The American Oncology Network is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.
The American Oncology Network (AON) is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.
The founders of AON expected a high level of success because of the organizations roots in Florida Cancer Specialists & Research Institute (FCS). AONs sister organization, FCS was established in 1984 and is thriving in the state of Florida. Today, it has more than 100 locations and is recognized as the largest privately held hematology/oncology practice in the United States. AONs management team was carried over from FCS.
As members of AON, oncology practices have access to resources like administration, management, billing, information technology, accounting, and other shared services that make it easier for oncologists to focus on caring for patients. Additionally, the central lab, central pathology, clinical research, and specialty pharmacy programs that AON provides help smaller oncology practices prevent from having to transfer their patients outside of the community treatment environment. The way AON operates varies from state to state, based on regulations and compliance. However, all member practices, large and small, can experience the benefits of the network.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More